Calling BS that Zoetis is not $240-$400 share price.

u/Tedious-Butcher · Reddit — r/ValueInvesting · August 25, 2026 at 10:37 · ⬆ 17 pts · 💬 60 comments  | View on Reddit ↗
AI Summary

Summary

  • Author argues Zoetis (ZTS) at ~$77 is unfairly priced at 2018 levels despite sales growing from $5.8B (2018) to ~$9.5B (2025) with 25%+ profit margins.
  • Thesis is simple momentum-plus-quality: rising revenue + high margins should push the stock higher, and pet owners will keep paying premium prices for trusted animal health products.
  • This is more opinion/speculation than rigorous DD — it ignores valuation, debt, patent expirations, and competitive dynamics.
Score 17
Comments 60
Upvote % 72%
Full Post Text
Ideas
u/Tedious-Butcher Reddit r/ValueInvesting
Zoetis has consistently grown sales year-over-year and maintains high profitability, which historically supports higher stock prices. If the market is overly focused on temporary headwinds (patent cliffs, debt), the stock may be mispriced relative to its stable cash generation. Author sees a long-term value opportunity, but the trade relies on the market eventually re-rating the stock once fears fade. Apoquel patent expiry (2025), Simparica expiry (2027), high debt load, weak consumer willingness to pay premium pet med prices, and lack of blockbuster pipeline replacements.
More from Reddit — r/ValueInvesting

This Reddit post, published August 25, 2026, features u/Tedious-Butcher discussing ZTS. 1 trade idea extracted by AI with direction and confidence scoring.

Speakers: u/Tedious-Butcher  · Tickers: ZTS